‘Piggybacking’ IOLs safer than IOL exchange

Article

A review of recent literature on the management of residual refractive error after cataract surgery found that piggyback intraocular lens (IOL) implantation is safer than and more accurate than an IOL exchange.

A review of recent literature on the management of residual refractive error after cataract surgery found that piggyback intraocular lens (IOL) implantation is safer than and more accurate than an IOL exchange.

Effectively comanaging femtosecond laser-assisted cataract surgery

Despite all of the inputs taken into consideration before surgery-accurate biometric analysis, selection and calculation of the adequate IOL, and modern surgical techniques-residual refractive error still occurs after cataract surgery.

According to the review’s authors, LASIK is the most accurate procedure to correct residual refractive error after cataract surgery. Lens-based procedures, IOL exchange or piggyback lens implantation, are also possible alternatives in cases with extreme ametropia, corneal abnormalities, or when excimer laser is not available.

“In this review, we found that piggyback IOL were safer and more accurate than IOL exchange,” the authors wrote. 

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.